Stefan Gross

Targeting cancer with kinase inhibitors.

Nicolas Stransky, Christoph Lengauer, Nicolas Stransky, 2015, The Journal of clinical investigation.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Tak W. Mak, Lenny Dang, Masato Sasaki, 2010, The Journal of experimental medicine.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Vivienne Marsh, S. Gross, B. Brandhuber, 2007, Clinical Cancer Research.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule

Dietmar Hoffmann, Jean-Pierre Marquette, Magali Mathieu, 2014, The Journal of Biological Chemistry.